Jpmorgan Chase & CO Regenxbio Inc. Transaction History
Jpmorgan Chase & CO
- $1.1 Trillion
- Q1 2024
A detailed history of Jpmorgan Chase & CO transactions in Regenxbio Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 3,722,553 shares of RGNX stock, worth $53.4 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
3,722,553
Previous 3,939,549
5.51%
Holding current value
$53.4 Million
Previous $70.7 Million
10.92%
% of portfolio
0.01%
Previous 0.01%
Shares
12 transactions
Others Institutions Holding RGNX
# of Institutions
192Shares Held
42.1MCall Options Held
80.6KPut Options Held
55.2K-
Black Rock Inc. New York, NY7.6MShares$109 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.88MShares$70 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.55MShares$65.3 Million3.78% of portfolio
-
State Street Corp Boston, MA3.12MShares$44.8 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.34MShares$19.2 Million0.0% of portfolio
About REGENXBIO Inc.
- Ticker RGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,230,000
- Market Cap $620M
- Description
- REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...